{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:00:43Z","timestamp":1771023643733,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K18009"],"award-info":[{"award-number":["19K18009"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Biochemically monitoring 21-hydroxylase deficiency (21-OHD) is challenging. Serum\/blood 17-hydroxyprogesterone (17OHP) measurements are normally used for this purpose. Urinary pregnanetriol (PT), a urinary metabolite of 17OHP, may also be used. Based on auxological data, we previously reported that the optimal first morning PT value fell in the range of 2.2\u20133.3 mg\/gCr (95% confidence interval of the mean) and 0.59-6.0 mg\/gCr (10<jats:sup>th<\/jats:sup> \u2013 90<jats:sup>th<\/jats:sup> percentile) for monitoring 21-OHD treatment. No report thus far has directly compared the first morning urinary PT value with the 17OHP value at various times during the day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the correlation between the first morning urinary PT value before glucocorticoid administration and the serum\/blood 17OHP value at three time points, namely, before and two and four hours after glucocorticoid administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This was a prospective study done at two children\u2019s hospitals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In total, 25 patients with 21-OHD aged 3-25 years were recruited. Their urinary PT levels and 17OHP levels were measured for three days within a total period of one week. The first morning PT value was collected on all three days. Dried blood spots and serum were used to measure 17OHP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The range for the first morning PT value for all the samples (n=69) was 0.10-56.1 mg\/gCr. A significant, positive correlation was found between the first morning PT and 17OHP values before medication (r=0.87, p&amp;lt;0.01), and weaker correlation was observed between the first morning PT and 17OHP values after medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The first morning PT correlated more significantly with 17OHP before the morning medication. Measuring the first morning PT value may be more practical and useful for monitoring 21-OHD biochemically.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.808254","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T05:31:12Z","timestamp":1643002272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["First Morning Pregnanetriol and 17-Hydroxyprogesterone Correlated Significantly in 21-Hydroxylase Deficiency"],"prefix":"10.3389","volume":"12","author":[{"given":"Tomoyo","family":"Itonaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hamajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021561","article-title":"Congenital Adrenal Hyperplasia","volume":"349","author":"Speiser","year":"2003","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66736-0","article-title":"Congenital Adrenal Hyperplasia","volume":"365","author":"Merke","year":"2005","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1297\/cpe.24.77","article-title":"Guidelines for Diagnosis and Treatment of 21-Hydroxylase Deficiency (2014 Revision)","volume":"24","author":"Ishii","year":"2015","journal-title":"Clin Pediatr Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000129677","article-title":"Patients With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency can Achieve Their Target Height: The Leipzig Experience","volume":"70","author":"Hoepffner","year":"2008","journal-title":"Horm Res"},{"key":"B6","article-title":"Auxological and Biochemical Parameters in Assessing Treatment of Infants and Toddlers With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency","volume":"6","author":"Einaudi","year":"1993","journal-title":"J Pediatr Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/adc.64.9.1235","article-title":"Monitoring Treatment in Congenital Adrenal Hyperplasia","volume":"64","author":"Appan","year":"1989","journal-title":"Arch Dis Child"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.146035","article-title":"Monitoring of Therapy in Congenital Adrenal Hyperplasia","volume":"56","author":"Dauber","year":"2010","journal-title":"Clin Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-4-200202190-00012","article-title":"NIH Conference. Future Directions in the Study and Management of Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency","volume":"136","author":"Merke","year":"2002","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7972","article-title":"Serum Cortisol and 17-Hydroxyprogesterone Interrelation in Classic 21-Hydroxylase Deficiency: Is Current Replacement Therapy Satisfactory","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1297\/cpe.16.45","article-title":"Pregnanetriol in the Range of 1.2-2.1 Mg\/M(2)\/Day as an Index of Optimal Control in CYP21A2 Deficiency","volume":"16","author":"Izawa","year":"2007","journal-title":"Clin Pediatr Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1297\/cpe.17.75","article-title":"The Range of 2.2-3.3 Mg\/gCr of Pregnanetriol in the First Morning Urine Sample as an Index of Optimal Control in CYP21 Deficiency","volume":"17","author":"Izawa","year":"2008","journal-title":"Clin Pediatr Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/srep25878","article-title":"Sex Differences in the Serum Level of Endogenous Ligands for Estrogen Receptor Beta in the Elderly Population","volume":"6","author":"Kobayashi","year":"2016","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the Freely Available Easy-to-Use Software 'EZR' for Medical Statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0064","article-title":"Hormonal Circadian Rhythms in Patients With Congenital Adrenal Hyperplasia: Identifying Optimal Monitoring Times and Novel Disease Biomarkers","volume":"173","author":"Debono","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2000.13.2.205","article-title":"Correlation of Blood-Spot 17-Hydroxyprogesterone Daily Profiles and Urinary Steroid Profiles in Congenital Adrenal Hyperplasia","volume":"13","author":"Erhardt","year":"2000","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105553","article-title":"Urinary Steroidomic Profiles by LC-MS\/MS to Monitor Classic 21-Hydroxylase Deficiency","volume":"198","author":"Pussard","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(74)80277-5","article-title":"Experience With Long-Term Therapy in Congenital Adrenal Hyperplasia","volume":"85","author":"Brook","year":"1974","journal-title":"J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/adc.53.2.132","article-title":"Management of Congenital Adrenal Hyperplasia. Urinary Steroid Estimations\u2013Review of Their Value","volume":"53","author":"Bailey","year":"1978","journal-title":"Arch Dis Child"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1982.03970390043014","article-title":"Urinary and Serum Steroid Concentrations in the Management of Congenital Adrenal Hyperplasia. Lack of Physiologic Correlations","volume":"136","author":"Hendricks","year":"1982","journal-title":"Am J Dis Child"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00438","article-title":"Height Velocity Defined Metabolic Control in Children With Congenital Adrenal Hyperplasia Using Urinary GC-MS Analysis","author":"Kamrath","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/000456328702400109","article-title":"Radioimmunoassay of Blood-Spot 17 Alpha-Hydroxyprogesterone in the Management of Congenital Adrenal Hyperplasia","volume":"24","author":"Robinson","year":"1987","journal-title":"Ann Clin Biochem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12653","article-title":"Variation in Absorption and Half-Life of Hydrocortisone Influence Plasma Cortisol Concentrations","volume":"82","author":"Hindmarsh","year":"2015","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.808254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T05:31:15Z","timestamp":1643002275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.808254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":23,"alternative-id":["10.3389\/fendo.2021.808254"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.808254","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"article-number":"808254"}}